Telangana: Natco Pharma has appointed Yarramshetty Krishna Rao as Senior Vice President – Operations at Mekaguda of the Company.
Yarramshetty Krishna Rao has overall 33 years of experience in the leading Indian Bulk Drug/API Manufacturing Industries, with 20 years of experience as Unit Head. Prior to joining Natco, he served at Dr. Reddy’s Laboratories Limited, Hyderabad, as Senior Director/Site Head – API manufacturing unit.
This appointment follows a series of senior leadership changes Natco Pharma unveiled last month, effective from June 1, 2025. As part of its organizational strengthening across various verticals, the company named Dilip Manikchand Dhore as Vice President – Corporate Quality Assurance, and Amber Roy as Associate Vice President – Distribution.
Additionally, Addagada Veeranarayana and Parupalli Sreenivasa Rao were appointed Associate Vice Presidents – Operations, while Kurada Venkata Maruti Ramchander was designated as Associate Vice President – Regulatory Affairs.
Earlier in April, Natco Pharma also announced the superannuation of two key executives: Dr. Ramesh Dandala, Executive Vice President – Technology Transfer, Intellectual Property Rights & Regulatory Affairs (API), and Tummala Venkata Rao, Vice President – Production.
NATCO Pharma Limited, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company has 9 manufacturing sites and 2 R&D facilities in India. The Company’s manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets.
